Shortcuts Reviewers 2018

open access

Vol 11, No 2 (2013)
Prace poglądowe (nadesłane)
Get Citation

Avanafil — new drug for treatment of erectile dysfunction

Bartosz Puchalski, Filip M. Szymański
Seksuologia Polska 2013;11(2).

open access

Vol 11, No 2 (2013)
Prace poglądowe (nadesłane)

Abstract

Phosphodiesterase type 5 inhibitors are currently the first-choice drugs for treatment of erectile dysfunction. Avanafil is a novel phosphodiesterase type 5 inhibitor. The drug is characterized by the fast onset of action, higher selectivity, better efficacy and lower rates of side effects. It should be administered in dose of 50 mg to 200 mg. Avanafil is associated with more spontaneous sexual activity.

Abstract

Phosphodiesterase type 5 inhibitors are currently the first-choice drugs for treatment of erectile dysfunction. Avanafil is a novel phosphodiesterase type 5 inhibitor. The drug is characterized by the fast onset of action, higher selectivity, better efficacy and lower rates of side effects. It should be administered in dose of 50 mg to 200 mg. Avanafil is associated with more spontaneous sexual activity.

Get Citation

Keywords

avanafil, erectile dysfunction, phosphodiesterase type 5 inhibitors

About this article
Title

Avanafil — new drug for treatment of erectile dysfunction

Journal

Seksuologia Polska (Polish Sexology)

Issue

Vol 11, No 2 (2013)

Bibliographic record

Seksuologia Polska 2013;11(2).

Keywords

avanafil
erectile dysfunction
phosphodiesterase type 5 inhibitors

Authors

Bartosz Puchalski
Filip M. Szymański

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl